Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1
Design Therapeutics announced the initiation of patient dosing in a Phase 1 multiple-ascending dose (MAD) trial of DT-818 for adults with myotonic dystrophy type-1 (DM1). DT-818 is a GeneTAC(®) small molecule designed to selectively reduce transcription of the mutant DMPK allele to address the underlying genetic cause of the disease.
Key figures
- Drug Name
- DT-818
- Phase Of Trial
- Phase 1
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.